precision medicine

Auransa is a clinical stage, AI-native biopharma with a proprietary AI platform that harnesses available human disease data to discover novel therapeutics and raise the standard of cancer care. Its platform mines heterogeneous human disease data, including 525,000+ gene expression profiles, to discover novel therapies for the most responsive patients. The company is advancing studies in liver cancer, heart-safe chemotherapy, and more, and partners with leading pharmaceutical companies and academic institutions.

AI platform for drug discoverydrug discovery programsgene expression profile analysismining human disease data

BioDawn Innovations is a research company focused on revolutionizing drug discovery using artificial intelligence, with a primary focus on aging-related illnesses and cancer. Founded by a group of seasoned researchers specialized in cancer and aging, the company develops AI to accelerate discovery of new therapeutics, builds an AI-powered platform for precision medicine tailored to each patient's needs, and uses AI algorithms to optimize efficacy and safety profiles of existing drugs.

AI-driven drug discoverybiomedical researchdrug optimization

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. It is pioneering a precision medicine approach targeting specific TGF-β superfamily members and pathways in oncology, inflammatory/immune, fibrotic, and metabolic diseases.

biologics developmentbiomarker stratificationdrug discoveryPK/PD modelingpreclinical developmentsmall molecule development